Status:
WITHDRAWN
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment
- Body mass index between 20 and 40
- Females of childbearing potential must use adequate birth control.
- Exclusion criteria:
- Subjects with previous use of insulin
- Type 1 diabetes
- Uncontrolled thyroid disease
- History of drug or alcohol abuse in the past year
- Any other clinically significant disease.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00387972
Start Date
May 1 2006
End Date
October 1 2007
Last Update
April 17 2015
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Clinical Trials Call Center
Tallassee, Alabama, United States, 36078
2
GSK Clinical Trials Call Center
Phoenix, Arizona, United States, 85016
3
GSK Clinical Trials Call Center
Tucson, Arizona, United States, 85710
4
GSK Clinical Trials Call Center
Beverly Hills, California, United States, 90211